ULCERATIVE COLITIS (UC)

This study compares two treatments for Crohn's disease and ulcerative colitis: using the drug infliximab alone versus combining it with another immune-suppressing drug. The goal is to see if the single drug can keep patients in remission without steroids just as well as the combo…

This study looks at whether adding a natural supplement called CurQD (made from curcumin and QingDai) can help people with active ulcerative colitis who are already taking Vedolizumab but still have symptoms. Researchers will review medical records from 400 patients to see if add…

This study looks at the long-term safety and effectiveness of a daily pill called upadacitinib for people with ulcerative colitis, a chronic bowel disease causing inflammation and ulcers. About 950 adults who didn't get better with earlier treatments or lost response will take th…

This study tests whether the drug risankizumab can help people with ulcerative colitis stay in remission (symptom-free) for up to a year. About 1,200 adults who already improved with risankizumab in an earlier study will either continue the drug or receive a placebo. The goal is …

This study is an early test of a new drug called ALTB-268, which may one day treat ulcerative colitis. It involves 24 healthy adults who receive a single dose of the drug or a placebo to check for side effects and how the drug moves through the body. The goal is to make sure the …

This study aims to understand how inflammatory bowel disease (IBD) affects patients' quality of life and what factors play a role. Researchers will survey 385 adults with Crohn's disease or ulcerative colitis about their symptoms, emotional well-being, social support, and daily f…

This study is collecting health information from 2000 people with Crohn's disease or ulcerative colitis to create tools that predict how well different treatments will work. The goal is to help doctors choose the right biologic or small-molecule drug for each patient. Participant…

This study reviews medical records of 120 adults with Crohn's disease or ulcerative colitis who switched from intravenous to subcutaneous (under-the-skin) vedolizumab. Researchers want to see if patients stay in remission and what dosing patterns they use. No new treatments are g…